# Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure

> **NCT04445285** · PHASE2 · RECRUITING · sponsor: **Jon Simmons** · enrollment: 44 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
- **DRUG:** 0.9%sodium chloride

## Key facts

- **NCT ID:** NCT04445285
- **Lead sponsor:** Jon Simmons
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-28
- **Primary completion:** 2021-11-30
- **Final completion:** 2022-02-28
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2021-05-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04445285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04445285, "Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04445285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*